Skip to main content
SpringerLink
Log in

Management of Advanced Breast Cancer

Defining the Role of Anastrozole

  • Drugs in Disease Management
  • Published:
Disease Management and Health Outcomes

Abstract

Breast cancer is the most common malignancy affecting women and imposes a substantial economic burden on society. Estrogen is thought to play a major role in both the initiation and promotion of hormone dependent breast cancer, and a number of well recognized risk factors for breast cancer reflect increased cumulative estrogen exposure (e.g. early menarche, late menopause).

Metastatic breast cancer is an incurable condition and the goals of treatment are to relieve symptoms, improve health-related quality of life and prolong life. Women with hormone receptor-positive disease are candidates for hormonal treatment. In contrast, chemotherapy is traditionally the treatment of choice in those with hormone receptor-negative disease or symptomatic visceral disease.

Anastrozole is a highly selective nonsteroidal type II aromatase inhibitor that suppresses plasma and intratumoral estrogen levels. The results of 2 multicenter, randomized, double-blind trials have shown anastrozole to be at least as effective as tamoxifen in the first-line treatment of postmenopausal women with advanced breast cancer, although survival data are lacking. In the smaller of these trials, the median time to disease progression was significantly prolonged (p = 0.005) in anastrozole, compared with tamoxifen, recipients (11.1 vs 5.6 months), although combined analysis of the 2 trials revealed no significant difference between an-astrozole and tamoxifen in terms of this end-point.

Similarly, anastrozole has been shown to be at least as effective as megestrol in the second-line treatment of postmenopausal women with advanced breast cancer in 2 multicenter randomized studies. Combined analysis of the studies revealed a significant survival advantage (p < 0.025) for anastrozole 1 mg/day, compared with megestrol 40mg 4 times daily, recipients (estimated hazard ratio 0.78; 97.5% confidence interval 0.6 to <1).

Tolerability is an important consideration in women with advanced breast cancer. The most common adverse events associated with anastrozole therapy were gastrointestinal disturbance, hot flushes, asthenia and pain. Anastrozole is associated with less vaginal bleeding and thromboembolic disease than tamoxifen and less bodyweight gain than megestrol. Anastrozole also appears to be a cost-effective option in the first- and second-line treatment of advanced breast cancer, although data are limited.

Conclusion: Current treatment guidelines support the use of anastrozole in the second-line treatment of postmenopausal women with advanced breast cancer. Although current treatment guidelines do not yet reflect this, data from recent, well designed studies demonstrate that anastrozole is likely to be a viable alternative to tamoxifen in the first-line treatment of postmenopausal women with advanced breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Dowsett M, on behalf of the ATAC Trialistss’ Group. Pharmacokinetics of Arimidex and tamoxifen alone and in combination in the ATAC adjuvant breast cancer trial [abstract]. Breast Cancer Res Treat 2000 Nov; 64: 64

    Google Scholar 

  2. Wiseman LR, Adkins JC. Anastrozole: a review of its use in the management of postmenopausal women with advanced breast cancer. Drugs Aging 1998 Oct; 13: 321–32

    Article  PubMed  CAS  Google Scholar 

  3. American Cancer Society. Statistics. American Cancer Society. Available from URL: http://www.cancer.org [Accessed 2001, Apr 20]

  4. Sainsbury JRC, Anderson TJ, Morgan DAL. ABC of breast diseases: breast cancer. BMJ 2000 Sep 23; 321: 745–50

    Article  PubMed  CAS  Google Scholar 

  5. National Comprehensive Cancer Network. NCCN Practice Guidelines for Breast Cancer. Oncology 2000 Nov; 14: 33–49

    Google Scholar 

  6. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001 Jan 25; 344(4): 276–85

    Article  PubMed  CAS  Google Scholar 

  7. Higa GM. Altering the estrogenic milieu of breast cancer with a focus on the new aromatase inhibitors. Pharmacotherapy 2000 Mar; 20: 280–91

    Article  PubMed  CAS  Google Scholar 

  8. Higa GM. New generation aromatase inhibitors in breast cancer: weighing out potential costs and benefits. Pharmacoeconomics 2000 Feb; 17: 121–32

    Article  PubMed  CAS  Google Scholar 

  9. McPherson K, Steel CM, Dixon JM. Breast cancer — epidemiology, risk factors, and genetics. BMJ 2000 Sep 9; 321: 624–8

    Article  PubMed  CAS  Google Scholar 

  10. Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years [letter]. Lancet 2000 May 20; 355: 1822

    Article  PubMed  CAS  Google Scholar 

  11. International Agency for Cancer Research. Globocan 2000: breast cancer incidences, mortality and prevalence worldwide. International Agency for Cancer Research. Available from: URL: http://www.iacr.fr [Accessed 2001, Apr 20]

  12. Kampert JB, Whittemore AS, Paffenbarager Jr RS. Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk. Am J Epidemiol 1988; 128: 962–79

    PubMed  CAS  Google Scholar 

  13. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972 Mar; 48: 605–13

    PubMed  CAS  Google Scholar 

  14. Bilmoria MM, Morrow M. The woman at increased risk for breast cancer: evaluation and management strategies. CA Cancer J Clin 1995 Sep/Oct; 45: 263–78

    Article  Google Scholar 

  15. Buell P. Changing incidence of breast cancer in Japanese-American women. J Natl Cancer Inst 1973 Nov; 51: 1479–83

    PubMed  CAS  Google Scholar 

  16. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRAC1 mutations in primary breast and ovarian carcinomas. Science 1994 Oct 7; 266: 120–2

    Article  PubMed  CAS  Google Scholar 

  17. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRACA2, to chromosome 13q12–13. Science 1994 Sep 30; 265: 2088–90

    Article  PubMed  CAS  Google Scholar 

  18. Legorreta AP, Brooks RJ, Leibowitz AN, et al. Cost of breast cancer treatment: a 4-year longitudinal study. Arch Intern Med 1996 Oct 28; 156: 2197–201

    Article  PubMed  CAS  Google Scholar 

  19. Will BP, Berthelot J-M, Le Petit C, et al. Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 2000 Apr; 36: 724–35

    Article  PubMed  CAS  Google Scholar 

  20. Moeremans K, Annemans L, Van Belle S. Long term medical costs of post-menopausal breast cancer therapy [abstract]. 36th Proc Am Soc Clin Oncol 2000 May 20; 19: 446

    Google Scholar 

  21. Richards MA, Braysher S, Gregory WM, et al. Advanced breast cancer: use of resources and cost implications. Br J Cancer 1993; 67: 856–60

    Article  PubMed  CAS  Google Scholar 

  22. Tran G, Burrell AD, Jackson DL, et al. Costs of failure of 1st line chemotherapy for advanced breast cancer in the UK. Br J Cancer 2000 Jul 1; 83 Suppl. 1: 49

    Google Scholar 

  23. Blamey RW, Wilson ARM, Patnick J. ABC of breast diseases: screening for breast cancer. BMJ 2000 Sep 16; 321: 689–93

    Article  PubMed  CAS  Google Scholar 

  24. Hughes KS, Roche CA, Whitney T, et al. The management of women at high risk of experiencing hereditary breast and ovarian cancer: the Lahey guidelines. Dis Manage Health Outcomes 2000 Apr; 7: 201–15

    Article  Google Scholar 

  25. Hayes TG, Peterson LE, Weinberg AD. Current guidelines for the diagnosis and treatment of breast cancer. Dis Manage Health Outcomes 1998 May; 3: 239–50

    Article  Google Scholar 

  26. Fornier M, Munster P, Seidman AD. Update on themanagement of advanced breast cancer. Oncology 1999 May; 13: 647–58

    PubMed  CAS  Google Scholar 

  27. Buzdar AU. Anastrozole: a new addition to the armamentarium against advanced breast cancer. Am J Clin Oncol 1998 Apr; 21: 161–6

    Article  PubMed  CAS  Google Scholar 

  28. Corry JF, Lønning PE. Systemic therapy in breast cancer: efficacy and cost utility. Pharmacoeconomics 1994; 5: 198–212

    Article  PubMed  CAS  Google Scholar 

  29. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin Cancer Res 1998; 4: 527–34

    PubMed  CAS  Google Scholar 

  30. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 1999 Oct; 21: 297–309

    Article  PubMed  CAS  Google Scholar 

  31. Stadtmauer EA, Os’Neill A, Goldstein LJ, et al. Conventionaldose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000 Apr 13; 342: 1069–76

    Article  PubMed  CAS  Google Scholar 

  32. Lotz J-P, Curé H, Janvier M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): results of the French Protocol PEGASE 04 [abstract no. 161]. Proc Am Soc Clin Oncol 1999 May 15; 18: 43a

    Google Scholar 

  33. Dowsett M. Biological background to aromatase inhibition. Breast 1996; 5(3): 196–201

    Article  Google Scholar 

  34. Miller WR. Aromatase inhibitors and breast cancer. Cancer Treat Rev 1997; 23: 171–87

    Article  PubMed  CAS  Google Scholar 

  35. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996; 74: 1286–91

    Article  PubMed  CAS  Google Scholar 

  36. Lonning PE, Geisler J, King N, et al. Influence of Arimidex (anastrozole), a non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer [abstract]. Breast Cancer Res Treat 1996; 37 Suppl.: 72

    Google Scholar 

  37. Plourde PV, Dyroff M, Dukes M. Arimidex®: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30(1): 103–11

    Article  PubMed  CAS  Google Scholar 

  38. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in post-menopausal patients with advanced breast cancer. Eur J Cancer A 1996 Mar; 32A: 404–12

    Article  PubMed  CAS  Google Scholar 

  39. Geisler J, Bernsten H, Ottestad L, et al. Neoadjuvant treatment with anastrozole (’Arimidex’) causes profound suppression of intra-tumor estrogen levels [abstract]. Proc Am Soc Clin Oncol 1999 May; 18: 82a

    Google Scholar 

  40. Bajetta E, Zilembo N, Bichisao E, et al. Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. Ann Oncol 2000 Aug; 11: 1017–22

    Article  PubMed  CAS  Google Scholar 

  41. Plourde PV, Yates RA, Dyroff M, et al. The effect of Arimidex™, a new potent aromatase inhibitor, on circulating estrogens in post-menopausal women [abstract]. Proc Am Soc Clin Oncol 1993 Mar; 12: 91

    Google Scholar 

  42. Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996 Feb; 73: 543–8

    Article  PubMed  CAS  Google Scholar 

  43. Wolter J, Robert N, Harvey H, et al. Arimidex (ZD1033): a phase I study of a new, selective orally active aromatase inhibitor in postmenopausal women with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 119

    Google Scholar 

  44. Wojtacki J, Kruszewski W, Sliwinska M, et al. Effect of nonsteroidal aromatase inhibitors (AI) on serum lipids profile in patients with breast cancer. Preliminary report [abstract]. Eur J Cancer 2000 Sep; 36 Suppl. 5: 71

    Google Scholar 

  45. AstraZeneca. Arimidex® (anastrozole) tablets prescribing information. AstraZeneca. Available from: URL: http://www.astrazeneca-us.com [Accessed 2001 May 2]

  46. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000 Nov 15; 18: 3758–67

    PubMed  CAS  Google Scholar 

  47. Bonneterre J, Thürlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex RandomizedGroup Efficacy and Tol-erability Study. J Clin Oncol 2000 Nov 15; 18: 3748–57

    PubMed  CAS  Google Scholar 

  48. Buzdar A, Nabholtz JM, Robertson JF, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal (Pm) women ≡ combined analysis from two identically designed multicenter trials [abstract]. Proc Am Soc Clin Oncol 2000; 19: 154

    Google Scholar 

  49. Bagley Jr CM, Rowbotham RK. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? [letter 3]. J Clin Oncol 2001 May; 19: 2578–9

    PubMed  Google Scholar 

  50. Tonkin K. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? [letter 4]. J Clin Oncol 2001 May; 19: 2579–80

    PubMed  CAS  Google Scholar 

  51. Buzdar A, Bonneterre J, Nabholtz JM, et al. Anastrozole (AN) versus tamoxifen (TAM) as first-line therapy for advanced breast cancer (ABC) in post-menopausal (PM) women: findings highlight the importance of receptor status assessment prior to treatment initiation [abstract 990]. Ann Oncol 2000; 11 Suppl. 4

    Article  Google Scholar 

  52. Milla-Santos A, Milla L, Rallo L, et al. Anastrozole vs tamoxifen in hormonodependent advanced breast cancer. A phase II randomized trial [abstract]. Breast Cancer Res Treat 2000 Nov; 64: 54

    Google Scholar 

  53. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in post-menopausal women with advanced breast carcinoma. Cancer 1997; 79: 730–9

    Article  PubMed  CAS  Google Scholar 

  54. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group [published erratum appears in Cancer 1999 Feb 15;85 (4):1010]. Cancer 1998 Sep 15; 83: 1142–52

    Article  PubMed  CAS  Google Scholar 

  55. Howell A, Buzdar A, Jonat W. Arimidex™ (anastrozole) -effective in advanced breast cancer (ABC) patients with visceral and liver metastases [abstract]. Breast Cancer Res Treat 1998; 50: 304

    Google Scholar 

  56. Harper-Wynne C, Coombes RC. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy. Eur J Cancer 1999 May; 35: 744–6

    Article  PubMed  CAS  Google Scholar 

  57. Simons WR, Bassi R, Gandhi S, et al. A comparison of the direct healthcare costs following disease progression (DP) with anastrozole (AN) and tamoxifen (TAM) in the first-line treatment of postmenopausal (PM) patients (pts) with advanced breast cancer (ABC) [abstract]. Alderly Park: AstraZeneca, 2001 (Data on file)

    Google Scholar 

  58. Simons WR, Grace EM. Cost-effectiveness of anastrozole compared to tamoxifen in the treatment of post-menopausal women with breast cancer [abstract]. Eur J Cancer 2000; 36 Suppl. 3: S7

    Google Scholar 

  59. Dranitsaris G, Leung P, Mather J, et al. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 2000 Aug; 11: 591–601

    Article  PubMed  CAS  Google Scholar 

  60. Drummond M, Thompson E, Howell A, et al. Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. J Drug Assess 1999; 2: 169–79

    Google Scholar 

  61. Simons WR, Bassi R, Gandhi S, et al. A comparison of qualityadjusted time to disease progression (QATTP) of anastrozole (AN) vs tamoxifen (TAM) as the first-line treatment of postmenopausal (PM) patients (pts) with advanced breast cancer (ABC) [abstract]. Alderly Park: AstraZeneca, 2001 (Data on file)

    Google Scholar 

  62. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999 Apr; 10: 377–84

    Article  PubMed  CAS  Google Scholar 

  63. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001 May; 19: 2596–606

    PubMed  CAS  Google Scholar 

  64. Costa SD, Kaufmann M. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? [letter]. J Clin Oncol 2001 May; 19: 2580

    PubMed  CAS  Google Scholar 

  65. Nabholtz JM, Bonneterre J, Buzdar A, et al. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer [reply: letter]. J Clin Oncol 2001 May; 19: 2580–2

    Google Scholar 

  66. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: doubleblind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998 Feb; 16: 453–61

    PubMed  CAS  Google Scholar 

  67. Thürlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Ann Oncol 1996; 7: 471–9

    Article  PubMed  Google Scholar 

  68. Paridaens R, Dirix LY, Beex L, et al. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): results of a randomized phase II trial [abstract no. 316]. Proc Am Soc Clin Oncol 2000 May 20; 19: 83

    Google Scholar 

  69. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000 Apr; 18: 1399–411

    PubMed  CAS  Google Scholar 

  70. Kvinnsland S, Anker G, Dirix L-Y, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000; 36: 976–82

    Article  PubMed  CAS  Google Scholar 

  71. Thürlimann B, Castiglione M, Hsu-Schmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 1997; 33: 1017–24

    Article  PubMed  Google Scholar 

  72. Bajetta E, Zilembo N, Bichisao E. Aromatase inhibitors in the treatment of postmenopausal breast cancer. Drugs Aging 1999 Oct; 15: 271–83

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Gillian M. Keating & Karen L. Goa

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M., Goa, K.L. Management of Advanced Breast Cancer. Dis-Manage-Health-Outcomes 9, 385–402 (2001). https://doi.org/10.2165/00115677-200109070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00115677-200109070-00004

Keywords

Search

Navigation